<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>代理总检察长 Todd Blanche 最近表示，司法部正在推动改变某些类型大麻在联邦法律下的分类，这标志着美国对毒品政策看法的显著转变。</p>
<p>根据 Blanche 的说法，获得 FDA 批准并获得州许可的大麻将在司法部的指导下从第一类药物重新分类为第三类药物。</p>
<p>第一类物质，如海洛因和 LSD，被视为极其危险且没有被接受的医疗用途，而第三类药物则被认为具有中等到较低的成瘾潜力。</p>
<p>司法部还计划在 6 月 29 日举行一次快速听证会，以审查有关大麻分类的更广泛变化。这表明更多的政策变化可能即将到来。这一举措与唐纳德·特朗普的行政命令一致，旨在加快大麻的重新分类，尽管这并没有完全在联邦层面合法化。</p>
<p>Blanche 解释说，这一决定旨在使医疗治疗更易获得，并促进科学研究。他指出：“这一重新分类允许对大麻的安全性和有效性进行研究，最终为患者提供更好的护理，并为医生提供更可靠的信息。”</p>
<p>白宫对此发展表示支持，发言人 Kush Desai 将其描述为增强与医疗用途相关的大麻研究的重要一步。</p>
<p>改变大麻的分类预计将减少对临床研究的限制，科学家们认为，由于大麻在理查德·尼克松总统任期内被列为第一类药物，这一研究在几十年里受到阻碍。</p>
<p>这一政策变化显示出联邦政府在重新思考大麻法规方面日益开放，同时试图平衡公共健康问题与科学研究的需求。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

TLRY

CURLF

TCNNF

GTBIF

纯美国大麻 ETF

另类收益 ETF -ETFMG

<p>美国司法部在代理检察长 Todd Blanche 的领导下，正计划将某些类型的大麻从第一类药物重新分类为第三类药物，这反映了药物政策的转变。此项变更旨在提高医疗治疗的可及性，并促进对大麻的科学研究。听证会定于 6 月 29 日举行，以讨论进一步的分类变更。白宫支持这一倡议，旨在减少因之前的第一类药物分类而阻碍的临床研究限制。这一政策变化表明联邦政府在重新评估大麻监管方面日益开放</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Acting Attorney General Todd Blanche recently shared that the Justice Department is moving to change the classification of some types of marijuana under federal law, which marks a notable shift in how the U.S. views drug policy.</p>
<div class="lb-trans"><p>代理总检察长 Todd Blanche 最近表示，司法部正在推动改变某些类型大麻在联邦法律下的分类，这标志着美国对毒品政策看法的显著转变。</p>
</div><p>According to Blanche, cannabis that is FDA-approved and state-licensed will be reclassified from Schedule I to Schedule III under the Justice Department's guidelines.</p>
<div class="lb-trans"><p>根据 Blanche 的说法，获得 FDA 批准并获得州许可的大麻将在司法部的指导下从第一类药物重新分类为第三类药物。</p>
</div><p>Schedule I substances, like heroin and LSD, are seen as extremely dangerous and have no accepted medical use, whereas Schedule III drugs are recognized as having a moderate to lower potential for dependency.</p>
<div class="lb-trans"><p>第一类物质，如海洛因和 LSD，被视为极其危险且没有被接受的医疗用途，而第三类药物则被认为具有中等到较低的成瘾潜力。</p>
</div><p>The Justice Department is also planning to hold a quick hearing on June 29 to look into broader changes regarding marijuana's classification. This suggests that more policy changes could be on the horizon. This move is in line with an executive order from Donald Trump aimed at speeding up the reclassification of cannabis, though it doesn't go as far as completely legalizing it at the federal level.</p>
<div class="lb-trans"><p>司法部还计划在 6 月 29 日举行一次快速听证会，以审查有关大麻分类的更广泛变化。这表明更多的政策变化可能即将到来。这一举措与唐纳德·特朗普的行政命令一致，旨在加快大麻的重新分类，尽管这并没有完全在联邦层面合法化。</p>
</div><p>Blanche explained that this decision is meant to make medical treatments more accessible and boost scientific research. &#34;This rescheduling allows for studies on the safety and effectiveness of marijuana, ultimately giving patients better care and providing doctors with more trustworthy information,&#34; he noted.</p>
<div class="lb-trans"><p>Blanche 解释说，这一决定旨在使医疗治疗更易获得，并促进科学研究。他指出：“这一重新分类允许对大麻的安全性和有效性进行研究，最终为患者提供更好的护理，并为医生提供更可靠的信息。”</p>
</div><p>The White House is on board with this development, with spokesperson Kush Desai describing it as a significant step toward enhancing research related to the medical use of cannabis.</p>
<div class="lb-trans"><p>白宫对此发展表示支持，发言人 Kush Desai 将其描述为增强与医疗用途相关的大麻研究的重要一步。</p>
</div><p>Changing marijuana's classification is expected to reduce restrictions on clinical research, which scientists have argued has been hindered for decades due to cannabis's Schedule I designation set during Richard Nixon's presidency.</p>
<div class="lb-trans"><p>改变大麻的分类预计将减少对临床研究的限制，科学家们认为，由于大麻在理查德·尼克松总统任期内被列为第一类药物，这一研究在几十年里受到阻碍。</p>
</div><p>This policy change shows a growing openness in the federal government to rethink cannabis regulations while trying to juggle public health concerns with the need for scientific research.</p>
<div class="lb-trans"><p>这一政策变化显示出联邦政府在重新思考大麻法规方面日益开放，同时试图平衡公共健康问题与科学研究的需求。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

美国计划将大麻重新分类为附表 III，并扩大其研究途径